IMV 過去の業績

過去基準チェック /06

IMVの過去数年間の業績に関するデータが不十分です。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	n/a
ネット・マージン	n/a
前回の決算情報	31 Dec 2022

Recent updates

IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%

Dec 03

IMV reports Q3 results

Nov 12

収支内訳

IMV の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:IMVI.F 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Dec 22	-38	17	0
30 Sep 22	-41	17	0
30 Jun 22	-43	18	0
31 Mar 22	-40	17	0
31 Dec 21	-37	16	0
30 Sep 21	-32	15	0
30 Jun 21	-28	13	0
31 Mar 21	-26	12	0
31 Dec 20	-26	11	0
30 Sep 20	-25	10	0
30 Jun 20	-24	9	0
31 Mar 20	-22	8	0
31 Dec 19	-21	8	0
30 Sep 19	-20	7	0
30 Jun 19	-19	7	0
31 Mar 19	-19	7	0
31 Dec 18	-16	7	0
30 Sep 18	-15	7	0
30 Jun 18	-12	6	0
31 Mar 18	-10	5	0
31 Dec 17	-10	5	0
30 Sep 17	-9	4	0
30 Jun 17	-8	4	-1
31 Mar 17	-7	3	-1
31 Dec 16	-7	3	0
30 Sep 16	-6	3	1
30 Jun 16	-6	3	3
31 Mar 16	-7	3	4
31 Dec 15	-6	3	3
30 Sep 15	-6	3	3
30 Jun 15	-6	3	3
31 Mar 15	-5	2	3
31 Dec 14	-6	3	3
30 Sep 14	-5	2	3
30 Jun 14	-5	2	3
31 Mar 14	-5	3	2

質の高い収益: IMVI.Fが高品質の収益を有しているかどうかを判断するにはデータが不十分です。

利益率の向上: IMVI.Fの利益率が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: IMVI.Fの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。

成長の加速: IMVI.Fの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。

収益対業界: IMVI.Fの過去 1 年間の収益成長がBiotechs業界平均を上回ったかどうかを判断するにはデータが不十分です。

株主資本利益率

高いROE: IMVI.Fは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。

IMV 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

IMV Inc. to Report Q3, 2022 Results on Nov 11, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)

IMV Inc. to Report Q4, 2020 Results on Mar 17, 2021

Earnings released

IMV Inc. to Report Q2, 2020 Results on Aug 12, 2020

Recent updates

IMV Inc. Files Form 15

Nasdaq to Delist the Common Shares of IMV

IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite Index

IMV Receives Nasdaq Delisting Notice

IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize Trial

High number of new directors

IMV Inc. Announces Board Changes

IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

Imv Inc. Announces Initial Data from the Ongoing Phase 2B Vitalize Trial in Patients with R/R Dlbcl

IMV Inc. to Report Q3, 2022 Results on Nov 11, 2022

IMV Inc. Announces Board Changes

IMV to cut ~33% workforce amid reorganization

High number of new directors

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

IMV receives Nasdaq non-compliance letter

High number of new directors

IMV Inc. Announces Andrew Sheldon Not Stand for Re-Election to the Board

IMV Inc. announced that it has received $25 million in funding from Horizon Technology Finance Management, LLC

IMV Inc. Appoints Michael P. Bailey as Chairman of the Board

IMV Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

IMV Inc Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

IMV Inc. announces new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients

IMV Inc. Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

IMV Inc. Announces Final Topline Results of the Decide1 Clinical Trial

CEO & Director Frederic Ors has left the company

High number of new directors

CEO & Director recently bought US$147k worth of stock

Chief Medical Officer Joanne Schindler has left the company

IMV names Jeremy Graff as chief scientific officer

Imv Inc. Leads Immunotherapy to Be Investigated in Breast Cancer

Independent Director has left the company

Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)

IMV Inc. to Report Q4, 2020 Results on Mar 17, 2021

New 90-day high: US$4.36

IMV Reports Update on COVID-19 Vaccine Program

IMV's vaccine candidate potentially effective against COVID-19, shares up 16%

New 90-day low: US$3.13

Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer

IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%

Revenue and earnings beat expectations

IMV reports Q3 results

IMV Inc. Appoints Andrew Hall as Chief Business Officer

IMV's T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck's Keytruda® in PD-L1 Positive Patients with r/r DLBCL

IMV Inc. Provides Updated Clinical Data from Phase 2 SPiReL Study Evaluating its T Cell Therapy in Combination with Merck’s Keytruda in Patients with R/R DLBCL

New 90-day low: US$3.15

IMV Inc Announces That Biomarkers Associated with Clinical Response in Patients with R/R DLBCL Treated with DPX-Survivac

New 90-day low: US$3.85

IMV Inc. Provides Updates on Its Vaccine Candidate, DPX-COVID-19, for the Prevention of Infection Caused by the Novel Coronavirus SARS-COV-2

Earnings released

IMV Inc. to Report Q2, 2020 Results on Aug 12, 2020

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06